MicroRNAs, or miRNAs, are short non-coding RNA molecules, typically only about 22 nucleotides long, that do not encode proteins. Instead, they act as fine-tuners of gene expression. First discovered in the roundworm Caenorhabditis elegans and since found across most eukaryotes, including humans, a single miRNA can regulate the activity of multiple genes simultaneously. This one-to-many regulatory capacity makes them especially interesting for complex, multi-gene disorders such as cancer. Because miRNAs show distinct expression patterns in healthy individuals, cancer patients, and even across different disease stages, scientists have increasingly viewed them as candidates for diagnostic and prognostic indicators, and in some cases as drug targets in their own right.

In the new study, Anushka Pravin Chawhan and Norine Dsouza of St. Xavier’s College in Mumbai set out to close a gap in the LUSC literature. While many previous studies had catalogued differentially expressed protein-coding genes in this cancer, miRNAs had not been broadly exploited as targets. The researchers mined open-access miRNA sequencing data from The Cancer Genome Atlas, or TCGA, applying filters for transcriptome profiling, miRNA-Seq, and miRNA expression quantification. They downloaded and processed the datasets using the R package TCGAAssembler2, then compared miRNA expression between primary solid tumour samples and adjacent normal tissue to find molecules behaving abnormally in cancer.

The differential expression analysis, carried out in RStudio with the DESeq2 package, produced a strikingly balanced picture. Using an adjusted p-value threshold of less than 0.05, the team identified 81 differentially expressed miRNAs in LUSC tumours. Of these, 41 were down-regulated, consistent with a tumour-suppressing role, while 40 were up-regulated, suggesting oncogenic behaviour. The classification rested on the log2 fold change in expression, with values below -0.1 marking potential tumour suppressors and values above 0.1 marking potential oncogenes. A volcano plot generated with ggplot2 visualised the split, and the full list of significant molecules was deposited in supplementary files accompanying the paper.

Identifying molecules that behave differently in tumours is only half the story, however. The more clinically urgent question is whether those differences actually matter for patients. To answer it, the authors performed Cox proportional hazards regression on 1,519 miRNAs, combining tumour miRNA expression data with clinical outcomes from TCGA. Patients were stratified into high-expression and low-expression groups for each miRNA, and a log-rank p-value below 0.05 flagged molecules with a significant impact on overall survival. The analysis revealed another 81 survival-related miRNAs: for 46 of them, low expression predicted better survival, while for 35, high expression was associated with improved outcomes.

The pivotal moment came when the two lists were compared. Seven miRNAs appeared in both: they were differentially expressed in tumours and simultaneously had a significant effect on how long patients lived. These seven candidates were miR-129-2, miR-181a-1, miR-501, miR-519a-1, miR-545, miR-6509, and miR-6761. The survival directions differed among them. High expression of miR-129-2, miR-501, and miR-6509 correlated with better overall survival, whereas low expression of miR-181a-1, miR-519a-1, miR-545, and miR-6761 was linked to the same favourable outcome. Each of the 74 remaining miRNAs in each list was unique to one analysis, underscoring how stringent the double filter really is.

To probe what these seven molecules actually do, the team turned to the MISIM v2 web tool, which infers miRNA functional similarity based on known miRNA-disease associations. Building an interaction network with only positive correlations between 0.5 and 1, they found that five of the seven candidates, namely miR-129-2, miR-181a-1, miR-501, miR-519a-1, and miR-545, formed an interconnected cluster. Functional enrichment analysis tied the group to critical biological processes including cell death, blood-tumour barrier permeability, chondrocyte development, chondrogenic differentiation, osteoclast genesis, and vascular inflammation, pointing to deep involvement in cell differentiation machinery.

The disease association analysis broadened the picture even further. The candidate miRNAs were predicted to be involved in a remarkable range of malignancies, including breast, gastric, hepatocellular, colon, prostate, thyroid, renal cell, urothelial, and cervical cancers, as well as lung adenocarcinoma, lung neoplasms, brain neoplasms, and chondrosarcoma. Intriguingly, the molecules were also linked to neurological conditions such as neuroinflammation and Parkinson’s disease, a connection the authors note follows naturally from their involvement in brain tumours. This cross-disease web suggests the seven miRNAs sit at regulatory hubs whose perturbation reverberates through many tissue types, which is precisely the kind of biology that makes a molecule valuable as a biomarker.

Much of the study’s credibility comes from how well its computational findings align with prior experimental work. High expression of miR-6509 has been shown to reduce proliferation and migration and increase apoptosis in hepatocellular and gastric cancer cell lines, and ovarian cancer patients with high miR-6509 enjoy better five-year survival. miR-501 has repeatedly emerged as a tumour suppressor in renal, lung, and prostate cancers, restricting tumour size and metastasis. miR-129-2 is down-regulated in several cancers by targeting genes such as SOX4, BZW1, and Wip1, and its over-expression drives tumour reduction, consistent with the better survival seen in high-expression LUSC patients here. miR-181a-1, by contrast, behaves as a tumour promoter in colorectal cancer, multiple myeloma, and non-small cell lung cancer, matching the study’s finding that low expression predicts better outcomes.

Not every candidate fits neatly into the existing literature. miR-545 presents a genuine contradiction: one study found high expression lowers cell viability in lung adenocarcinoma and LUSC cell lines, yet the same work reported that the molecule promotes proliferation in HFL1 lung fibroblasts, cells that themselves can promote non-small cell lung cancer. The authors call for further clarity on this molecule, even as they note it has been validated as a biomarker in oncological studies. miR-519a shows similarly mixed signals, with high expression linked to poorer survival in liver and breast cancer, and one non-small cell lung cancer study, limited to adenocarcinoma cell lines, contradicting the present findings. Most tantalising of all, miR-6509 and miR-6761 had never before been implicated in LUSC, and the authors propose their involvement for the first time.

The authors are careful about what their results can and cannot claim. Everything rests on computational analysis of public datasets, and they emphasise that experimental validation is essential before any clinical translation. Knockdown and overexpression studies, in vitro experiments, animal models, and eventually clinical trials would all be needed to confirm efficacy, safety, and practical applicability, and to establish protocols for real-world patient care. Still, the logic of the approach is compelling: by demanding that a molecule be both dysregulated in tumours and statistically tied to patient survival, the study filters hundreds of candidates down to seven with genuine clinical potential. If laboratory work bears out the computational signals, these microRNAs could eventually feed into diagnostic panels for earlier detection, prognostic tools for personalised risk assessment, and even RNA-based therapeutics, offering a new molecular foothold against one of medicine’s most stubborn cancers.

Subject of Research: Computational identification of survival-associated microRNAs in lung squamous cell carcinoma

Article Title: Identification of key microRNAs in lung squamous cell carcinoma: a computational study

Article References: Chawhan, A. P., & Dsouza, N. (2025). Identification of key microRNAs in lung squamous cell carcinoma: a computational study. Discover Biotechnology, 2(1), Article 4. https://doi.org/10.1007/s44340-025-00011-4

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00011-4

Keywords: microRNA, lung squamous cell carcinoma, TCGA, biomarkers, differential expression, survival analysis, Cox regression, non-small cell lung cancer, bioinformatics, oncogenes, tumor suppressors, precision medicine